C Thomas1, A Neisius, F C Roos, C Hampel, J W Thüroff. 1. Klinik und Poliklinik für Urologie, Universitätsmedizin Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland, christian.thomas@unimedizin-mainz.de.
Abstract
BACKGROUND: Robot-assisted laparoscopic radical prostatectomy (RALP) has been rapidly adopted as a standard approach for surgical treatment of organ-confined prostate cancer. Despite additional costs, RALP seems to provide better functional and oncological outcomes and less blood loss compared to open radical prostatectomy (ORP). However, prospective randomized studies are still missing. PURPOSE: Based on the current literature, this review reports about the role of RALP in prostate cancer treatment. Its functional and oncologic outcomes as well as complication rates are compared to ORP. Particularly, the role of RALP in nonorgan-confined tumors will be discussed. RESULTS: Based on the current literature, RALP provides better continence and potency rates as compared to ORP. Moreover, the incidence of positive surgical margins seems to be reduced. However, there is conflicting data regarding the role of RALP in nonorgan-confined prostate cancer. Regarding long-term oncologic outcomes, RALP seems to be comparable to ORP.
BACKGROUND: Robot-assisted laparoscopic radical prostatectomy (RALP) has been rapidly adopted as a standard approach for surgical treatment of organ-confined prostate cancer. Despite additional costs, RALP seems to provide better functional and oncological outcomes and less blood loss compared to open radical prostatectomy (ORP). However, prospective randomized studies are still missing. PURPOSE: Based on the current literature, this review reports about the role of RALP in prostate cancer treatment. Its functional and oncologic outcomes as well as complication rates are compared to ORP. Particularly, the role of RALP in nonorgan-confined tumors will be discussed. RESULTS: Based on the current literature, RALP provides better continence and potency rates as compared to ORP. Moreover, the incidence of positive surgical margins seems to be reduced. However, there is conflicting data regarding the role of RALP in nonorgan-confined prostate cancer. Regarding long-term oncologic outcomes, RALP seems to be comparable to ORP.
Authors: Vincenzo Ficarra; Giacomo Novara; Thomas E Ahlering; Anthony Costello; James A Eastham; Markus Graefen; Giorgio Guazzoni; Mani Menon; Alexandre Mottrie; Vipul R Patel; Henk Van der Poel; Raymond C Rosen; Ashutosh K Tewari; Timothy G Wilson; Filiberto Zattoni; Francesco Montorsi Journal: Eur Urol Date: 2012-06-01 Impact factor: 20.096
Authors: Elyn H Wang; James B Yu; Cary P Gross; Marc C Smaldone; Nilay D Shah; Quoc-Dien Trinh; Paul L Nguyen; Maxine Sun; Leona C Han; Simon P Kim Journal: J Urol Date: 2014-09-19 Impact factor: 7.450
Authors: G Gandaglia; Q-D Trinh; J C Hu; J Schiffmann; A Becker; F Roghmann; I Popa; Z Tian; P Perrotte; F Montorsi; A Briganti; P I Karakiewicz; M Sun; F Abdollah Journal: Eur J Surg Oncol Date: 2014-01-02 Impact factor: 4.424
Authors: Vincenzo Ficarra; Giacomo Novara; Raymond C Rosen; Walter Artibani; Peter R Carroll; Anthony Costello; Mani Menon; Francesco Montorsi; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Timothy G Wilson; Filiberto Zattoni; Alexandre Mottrie Journal: Eur Urol Date: 2012-06-01 Impact factor: 20.096
Authors: Hendrik Isbarn; Manuela Wanner; Georg Salomon; Thomas Steuber; Thorsten Schlomm; Jens Köllermann; Guido Sauter; Alexander Haese; Hans Heinzer; Hartwig Huland; Markus Graefen Journal: BJU Int Date: 2009-12-11 Impact factor: 5.588
Authors: Tomás Merino; Ignacio F San Francisco; Pablo A Rojas; Piero Bettoli; Alvaro Zúñiga; Pelayo Besa Journal: BMC Cancer Date: 2013-11-08 Impact factor: 4.430
Authors: Margit Pohle; Ahmed Magheli; Tom Fischer; Carsten Kempkensteffen; Jonas Busch; Hannes Cash; Kurt Miller; Stefan Hinz Journal: Adv Ther Date: 2017-01-04 Impact factor: 3.845